Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: An NYGOG and ECOG study

Howard S. Hochster, Elizabeth R. Plimack, John Mandeli, Scott Wadler, Carolyn Runowicz, Gary Goldberg, James Speyer, Robert Wallach, Franco Muggia

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective. To determine the toxicity and efficacy of combined therapy with cisplatin and prolonged infusion topotecan as front line therapy in women with epithelial ovarian cancer. Patients and methods. Women with previously untreated, measurable and non-measurable epithelial ovarian cancer, stages Ic-IV were eligible. Patients were treated with cisplatin 75 mg/m2 on day 1, followed by topotecan 0.3 to 0.4 mg/m2/day given as a continuous infusion over 14-21 days, every 28 days. Dose levels and duration of infusion were adjusted for toxicity as appropriate. Patients were evaluated for response to treatment and treatment toxicity by standard NYGOG criteria. Results. Sixty patients were enrolled. Among the 20 patients with post-surgical residual disease >2 cm, 80% [95% CI (56.3%, 94.3%)] demonstrated an objective response to therapy. The median progression-free survival for all 60 patients enrolled was 19.3 months with a median overall survival of 45.6 months given the median follow-up of 55 months (range 6-81 months). Five year survival is estimated to be 41%. Toxicity was observed in the first four patients treated with topotecan (0.4 mg/m2/day × 21 days) and dosing was continued at 0.3 mg/m2/day × 14 days thereafter. Of the 56 patients treated at the amended dose level, marrow suppression continued to be dose-limiting, with 86% of patients experiencing grade 3 or 4 neutropenia, 55% experiencing grade 3 or 4 thrombocytopenia and 50% of patients experiencing grade 3 or 4 anemia. Nonetheless, only 11/245 cycles administered were associated with febrile neutropenia and/or infection (8 port-related). Other non-hematologic toxicity was as expected. There were no treatment-related deaths. Conclusion. This large, multicenter phase II study of prolonged infusion topotecan in combination with cisplatin demonstrated similar response, time to progression and survival compared with reported results of taxane and platinum combinations. Hematologic toxicity was greater but tolerated. Further studies investigating topotecan in combination with platinum therapy as a first line agent are warranted.

Original languageEnglish (US)
Pages (from-to)324-329
Number of pages6
JournalGynecologic Oncology
Volume100
Issue number2
DOIs
StatePublished - Feb 2006

Fingerprint

Topotecan
Ovarian Neoplasms
Cisplatin
Therapeutics
Platinum
Survival
Febrile Neutropenia
Neutropenia
Reaction Time
Disease-Free Survival
Anemia
Bone Marrow

Keywords

  • First-line chemotherapy
  • Infusional chemotherapy
  • Ovarian cancer
  • Platinum
  • Topotecan

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Hochster, H. S., Plimack, E. R., Mandeli, J., Wadler, S., Runowicz, C., Goldberg, G., ... Muggia, F. (2006). Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: An NYGOG and ECOG study. Gynecologic Oncology, 100(2), 324-329. https://doi.org/10.1016/j.ygyno.2005.08.059

Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer : An NYGOG and ECOG study. / Hochster, Howard S.; Plimack, Elizabeth R.; Mandeli, John; Wadler, Scott; Runowicz, Carolyn; Goldberg, Gary; Speyer, James; Wallach, Robert; Muggia, Franco.

In: Gynecologic Oncology, Vol. 100, No. 2, 02.2006, p. 324-329.

Research output: Contribution to journalArticle

Hochster, HS, Plimack, ER, Mandeli, J, Wadler, S, Runowicz, C, Goldberg, G, Speyer, J, Wallach, R & Muggia, F 2006, 'Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: An NYGOG and ECOG study', Gynecologic Oncology, vol. 100, no. 2, pp. 324-329. https://doi.org/10.1016/j.ygyno.2005.08.059
Hochster, Howard S. ; Plimack, Elizabeth R. ; Mandeli, John ; Wadler, Scott ; Runowicz, Carolyn ; Goldberg, Gary ; Speyer, James ; Wallach, Robert ; Muggia, Franco. / Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer : An NYGOG and ECOG study. In: Gynecologic Oncology. 2006 ; Vol. 100, No. 2. pp. 324-329.
@article{4b1f5294f9f544e88df0ad157016d2dd,
title = "Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: An NYGOG and ECOG study",
abstract = "Objective. To determine the toxicity and efficacy of combined therapy with cisplatin and prolonged infusion topotecan as front line therapy in women with epithelial ovarian cancer. Patients and methods. Women with previously untreated, measurable and non-measurable epithelial ovarian cancer, stages Ic-IV were eligible. Patients were treated with cisplatin 75 mg/m2 on day 1, followed by topotecan 0.3 to 0.4 mg/m2/day given as a continuous infusion over 14-21 days, every 28 days. Dose levels and duration of infusion were adjusted for toxicity as appropriate. Patients were evaluated for response to treatment and treatment toxicity by standard NYGOG criteria. Results. Sixty patients were enrolled. Among the 20 patients with post-surgical residual disease >2 cm, 80{\%} [95{\%} CI (56.3{\%}, 94.3{\%})] demonstrated an objective response to therapy. The median progression-free survival for all 60 patients enrolled was 19.3 months with a median overall survival of 45.6 months given the median follow-up of 55 months (range 6-81 months). Five year survival is estimated to be 41{\%}. Toxicity was observed in the first four patients treated with topotecan (0.4 mg/m2/day × 21 days) and dosing was continued at 0.3 mg/m2/day × 14 days thereafter. Of the 56 patients treated at the amended dose level, marrow suppression continued to be dose-limiting, with 86{\%} of patients experiencing grade 3 or 4 neutropenia, 55{\%} experiencing grade 3 or 4 thrombocytopenia and 50{\%} of patients experiencing grade 3 or 4 anemia. Nonetheless, only 11/245 cycles administered were associated with febrile neutropenia and/or infection (8 port-related). Other non-hematologic toxicity was as expected. There were no treatment-related deaths. Conclusion. This large, multicenter phase II study of prolonged infusion topotecan in combination with cisplatin demonstrated similar response, time to progression and survival compared with reported results of taxane and platinum combinations. Hematologic toxicity was greater but tolerated. Further studies investigating topotecan in combination with platinum therapy as a first line agent are warranted.",
keywords = "First-line chemotherapy, Infusional chemotherapy, Ovarian cancer, Platinum, Topotecan",
author = "Hochster, {Howard S.} and Plimack, {Elizabeth R.} and John Mandeli and Scott Wadler and Carolyn Runowicz and Gary Goldberg and James Speyer and Robert Wallach and Franco Muggia",
year = "2006",
month = "2",
doi = "10.1016/j.ygyno.2005.08.059",
language = "English (US)",
volume = "100",
pages = "324--329",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer

T2 - An NYGOG and ECOG study

AU - Hochster, Howard S.

AU - Plimack, Elizabeth R.

AU - Mandeli, John

AU - Wadler, Scott

AU - Runowicz, Carolyn

AU - Goldberg, Gary

AU - Speyer, James

AU - Wallach, Robert

AU - Muggia, Franco

PY - 2006/2

Y1 - 2006/2

N2 - Objective. To determine the toxicity and efficacy of combined therapy with cisplatin and prolonged infusion topotecan as front line therapy in women with epithelial ovarian cancer. Patients and methods. Women with previously untreated, measurable and non-measurable epithelial ovarian cancer, stages Ic-IV were eligible. Patients were treated with cisplatin 75 mg/m2 on day 1, followed by topotecan 0.3 to 0.4 mg/m2/day given as a continuous infusion over 14-21 days, every 28 days. Dose levels and duration of infusion were adjusted for toxicity as appropriate. Patients were evaluated for response to treatment and treatment toxicity by standard NYGOG criteria. Results. Sixty patients were enrolled. Among the 20 patients with post-surgical residual disease >2 cm, 80% [95% CI (56.3%, 94.3%)] demonstrated an objective response to therapy. The median progression-free survival for all 60 patients enrolled was 19.3 months with a median overall survival of 45.6 months given the median follow-up of 55 months (range 6-81 months). Five year survival is estimated to be 41%. Toxicity was observed in the first four patients treated with topotecan (0.4 mg/m2/day × 21 days) and dosing was continued at 0.3 mg/m2/day × 14 days thereafter. Of the 56 patients treated at the amended dose level, marrow suppression continued to be dose-limiting, with 86% of patients experiencing grade 3 or 4 neutropenia, 55% experiencing grade 3 or 4 thrombocytopenia and 50% of patients experiencing grade 3 or 4 anemia. Nonetheless, only 11/245 cycles administered were associated with febrile neutropenia and/or infection (8 port-related). Other non-hematologic toxicity was as expected. There were no treatment-related deaths. Conclusion. This large, multicenter phase II study of prolonged infusion topotecan in combination with cisplatin demonstrated similar response, time to progression and survival compared with reported results of taxane and platinum combinations. Hematologic toxicity was greater but tolerated. Further studies investigating topotecan in combination with platinum therapy as a first line agent are warranted.

AB - Objective. To determine the toxicity and efficacy of combined therapy with cisplatin and prolonged infusion topotecan as front line therapy in women with epithelial ovarian cancer. Patients and methods. Women with previously untreated, measurable and non-measurable epithelial ovarian cancer, stages Ic-IV were eligible. Patients were treated with cisplatin 75 mg/m2 on day 1, followed by topotecan 0.3 to 0.4 mg/m2/day given as a continuous infusion over 14-21 days, every 28 days. Dose levels and duration of infusion were adjusted for toxicity as appropriate. Patients were evaluated for response to treatment and treatment toxicity by standard NYGOG criteria. Results. Sixty patients were enrolled. Among the 20 patients with post-surgical residual disease >2 cm, 80% [95% CI (56.3%, 94.3%)] demonstrated an objective response to therapy. The median progression-free survival for all 60 patients enrolled was 19.3 months with a median overall survival of 45.6 months given the median follow-up of 55 months (range 6-81 months). Five year survival is estimated to be 41%. Toxicity was observed in the first four patients treated with topotecan (0.4 mg/m2/day × 21 days) and dosing was continued at 0.3 mg/m2/day × 14 days thereafter. Of the 56 patients treated at the amended dose level, marrow suppression continued to be dose-limiting, with 86% of patients experiencing grade 3 or 4 neutropenia, 55% experiencing grade 3 or 4 thrombocytopenia and 50% of patients experiencing grade 3 or 4 anemia. Nonetheless, only 11/245 cycles administered were associated with febrile neutropenia and/or infection (8 port-related). Other non-hematologic toxicity was as expected. There were no treatment-related deaths. Conclusion. This large, multicenter phase II study of prolonged infusion topotecan in combination with cisplatin demonstrated similar response, time to progression and survival compared with reported results of taxane and platinum combinations. Hematologic toxicity was greater but tolerated. Further studies investigating topotecan in combination with platinum therapy as a first line agent are warranted.

KW - First-line chemotherapy

KW - Infusional chemotherapy

KW - Ovarian cancer

KW - Platinum

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=30444457230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30444457230&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2005.08.059

DO - 10.1016/j.ygyno.2005.08.059

M3 - Article

C2 - 16253316

AN - SCOPUS:30444457230

VL - 100

SP - 324

EP - 329

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -